Delenex Therapeutics AG
Switzerland
acquired
acquired
Stage
1
Investors
About
Delenex Therapeutics AG was a clinical-stage biopharmaceutical company focused on developing antibody therapeutics using its proprietary PENT(R)Body platform to create potent and stable antibody fragments for treating diseases including oncology, Crohn's disease, and psoriasis.
Explore Delenex Therapeutics AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.